Shivaee A, Sedighi M, Imani Fooladi A A
Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Ann Ig. 2020 Nov-Dec;32(6):648-663. doi: 10.7416/ai.2019.2386.
Cancer is considered as one of the leading causes of death today. The wrong lifestyles have led to an increase in the incidence rate of this deadly disease. There are many complications associated with common treatments of this disease. Immunotherapy is one of the new approaches taken recently. The purpose of this systematic review was to evaluate the studies on Staphylococcus aureus enterotoxins as a treatment of cancer worldwide.
We conducted a systematic review of articles published in PubMed, Cochrane, Scopus and Google scholar databases from 1995 to 2016 to evaluate the effects of Staphylococci enterotoxins on cancer.
Eligible studies were evaluated qualitatively based on a checklist prepared by two independent reviewers, and they were subsequently matched.
Our review identified 97 records through searching PubMed and Cochrane database and 1306 records through searching Google scholar and Scopus. Forty six studies were excluded from PubMed and Cochrane database and 1281 studies were excluded from Google scholar and Scopus after screening abstracts and titles. Therefore, our systematic review was based on 51 publications on PubMed and Cochrane, and 25 publications on Google scholar and Scopus, which met our criteria. Staphylococcal enterotoxin A was the most commonly used toxin in these studies. The side effects of using this toxin in immunotherapy have been reported to be low and all studies have identified this toxin as a suitable option for immunotherapy.
The data obtained from these studies showed that due to the low rates of complications, Staphylococcal enterotoxins have the potential to induce immune system against various cancers as super-antigens. Therefore, they can be considered as a suitable candidate for immunotherapy of cancer.
癌症被认为是当今主要的死亡原因之一。错误的生活方式导致了这种致命疾病发病率的上升。该疾病的常见治疗方法存在许多并发症。免疫疗法是最近采用的新方法之一。本系统评价的目的是评估全球范围内关于金黄色葡萄球菌肠毒素作为癌症治疗方法的研究。
我们对1995年至2016年发表在PubMed、Cochrane、Scopus和谷歌学术数据库中的文章进行了系统评价，以评估葡萄球菌肠毒素对癌症的影响。
根据两位独立评审员编制的检查表对符合条件的研究进行定性评估，随后进行匹配。
我们的综述通过搜索PubMed和Cochrane数据库识别出97条记录，通过搜索谷歌学术和Scopus识别出1306条记录。在筛选摘要和标题后，从PubMed和Cochrane数据库中排除了46项研究，从谷歌学术和Scopus中排除了1281项研究。因此，我们的系统评价基于PubMed和Cochrane上符合我们标准的51篇出版物，以及谷歌学术和Scopus上的25篇出版物。金黄色葡萄球菌肠毒素A是这些研究中最常用的毒素。据报道，在免疫疗法中使用这种毒素的副作用较低，所有研究都将这种毒素确定为免疫疗法的合适选择。
从这些研究中获得的数据表明，由于并发症发生率较低，葡萄球菌肠毒素作为超抗原具有诱导免疫系统对抗各种癌症的潜力。因此，它们可被视为癌症免疫疗法的合适候选者。
